Related references
Note: Only part of the references are listed.Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Russell W. Jenkins et al.
CANCER DISCOVERY (2018)
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy
Minan Wang et al.
FASEB JOURNAL (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
A Critical need for Better Cancer Immunotherapy Models: Are Organotypic Tumor spheroid Cultures the Answer?
Justin M. Balko et al.
CANCER DISCOVERY (2018)
Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody
Kyoko Yamaguchi et al.
CANCER SCIENCE (2018)
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Rachel Marty et al.
CELL (2018)
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (vol 24, pg 4960, 2018)
Richard W. Joseph et al.
CLINICAL CANCER RESEARCH (2018)
Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade
Daniel S. W. Tan
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Shuguang Tan et al.
NATURE COMMUNICATIONS (2017)
Human Tumor-infiltrating Myeloid Cells: Phenotypic and Functional Diversity
Louise A. Elliott et al.
FRONTIERS IN IMMUNOLOGY (2017)
Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice
Julie Lang et al.
BLOOD ADVANCES (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Humanized hemato-lymphoid system mice
Alexandre P. A. Theocharides et al.
HAEMATOLOGICA (2016)
Receptor editing and genetic variability in human autoreactive B cells
Julie Lang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Humanized hemato-lymphoid system mice
Alexandre P. A. Theocharides et al.
HAEMATOLOGICA (2016)
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2016)
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng et al.
CLINICAL CANCER RESEARCH (2016)
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
Samer Alzoubi et al.
ONCOTARGET (2016)
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
Sofia R. Gameiro et al.
ONCOTARGET (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Seth B. Coffelt et al.
TRENDS IN IMMUNOLOGY (2015)
The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
Shiguo Zhu et al.
PHARMACEUTICAL RESEARCH (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
CD4 Ligation on Human Blood Monocytes Triggers Macrophage Differentiation and Enhances HIV Infection
Anjie Zhen et al.
JOURNAL OF VIROLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Development and function of human innate immune cells in a humanized mouse model
Anthony Rongvaux et al.
NATURE BIOTECHNOLOGY (2014)
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Hatem Soliman et al.
PLOS ONE (2014)
HDAC inhibitors and immunotherapy; a double edged sword?
Michiel Kroesen et al.
ONCOTARGET (2014)
The anticancer effects of HDAC inhibitors require the immune system
Alison C. West et al.
ONCOIMMUNOLOGY (2014)
Studies of Lymphocyte Reconstitution in a Humanized Mouse Model Reveal a Requirement of T Cells for Human B Cell Maturation
Julie Lang et al.
JOURNAL OF IMMUNOLOGY (2013)
Conservation and divergence in the transcriptional programs of the human and mouse immune systems
Tal Shay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Genomic responses in mouse models poorly mimic human inflammatory diseases
Junhee Seok et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2nullIl2rγnull mouse model: A multivariable optimization approach
Julie Lang et al.
CLINICAL IMMUNOLOGY (2011)
Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
Todd M. Pitts et al.
CLINICAL CANCER RESEARCH (2010)
Of mice and not men: Differences between mouse and human immunology
J Mestas et al.
JOURNAL OF IMMUNOLOGY (2004)
Share Paper
